ASCT2 targeting antibody-drug conjugate - ADC Therapeutics
Latest Information Update: 19 May 2024
At a glance
- Originator ADC Therapeutics
- Class Alkaloids; Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer